Drug

HN2301 clinical trials

studies test it: 3
open now: 2
in phase 3: 0
first study started: 2025

How each study uses HN2301 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the HN2301 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

HN2301 injection: 3
in vivo cart: 2

Studies by the year they started

3 studies that test it; most in 2026 (2)

Studies that test HN2301, by start year
Year	Studies
2025	1
2026	2

By phase

A phase 1/2 study counts in both.

Phase 1: 2
No phase: 1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Myasthenia Gravis: 2
Lupus Erythematosus, Systemic: 1

Who runs them

Industry 3 · Other 0

Shenzhen MagicRNA Biotechnology Co., Ltd (3)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test HN2301.

May 2027Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)Phase 1 · Shenzhen MagicRNA Biotechnology Co., Ltd

Studies

Open first, then newest update. How each study uses HN2301 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.